TXMD

Elite Trades From Anywhere Elite Trades All Summer

$100 Off Your First Year Get Elite For Just $199.50

Days

Hours

Mins

Sec

Claim Now

Peers: CPHI RMTI BGM CPIX CTOR SCYX DERM ASRT CRDL SCLX

| Held by: VTI VXF DFAC DFSU DCOR

Scroll to Statements

Index	-
Market Cap	24.42M
Enterprise Value	21.83M
Income	0.18M
Sales	3.35M
Book/sh	2.33
Cash/sh	0.73
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	1
IPO	Jan 03, 2002

P/E	137.01
Forward P/E	-
PEG	-
P/S	7.29
P/B	0.91
P/C	2.90
P/FCF	9.15
EV/EBITDA	-
EV/Sales	6.52
Quick Ratio	2.63
Current Ratio	2.63
Debt/Eq	0.22
LT Debt/Eq	0.18
Option/Short	Yes / Yes

EPS (ttm)	0.02
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	83.18% 72.84%
Sales past 3/5Y	-64.91% -45.84%
EPS Y/Y TTM	108.52%
Sales Y/Y TTM	82.13%
EPS Q/Q	114.51%
Sales Q/Q	84.22%
Earnings	Mar 30 AMC
EPS/Sales Surpr.	- -

Insider Own	6.87%
Insider Trans	0.00%
Inst Own	33.96%
Inst Trans	11.42%
ROA	0.23%
ROE	0.32%
ROIC	0.56%
Gross Margin	57.56%
Oper. Margin	-111.66%
Profit Margin	5.34%
SMA20	2.20%
SMA50	2.27%
SMA200	12.89%
Trades

Shs Outstand	11.57M
Shs Float	10.78M
Short Float	0.43%
Short Ratio	1.21
Short Interest	0.05M
52W High	2.95 -28.47%
52W Low	0.99 113.13%
Volatility	9.08% 8.05%
ATR (14)	0.16
RSI (14)	51.50
Beta	0.60
Rel Volume	0.36
Avg Volume	38.12K
Volume	13,599

Perf Week	3.94%
Perf Month	3.43%
Perf Quarter	5.50%
Perf Half Y	28.66%
Perf YTD	29.45%
Perf Year	85.09%
Perf 3Y	-48.79%
Perf 5Y	-96.23%
Perf 10Y	-99.51%
Recom	3.00
Target Price	5.00
Prev Close	2.16
Price	2.11
Change	-2.31%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-07-20	Downgrade	Jefferies	Hold → Underperform
May-19-20	Downgrade	JP Morgan	Overweight → Neutral
Dec-02-19	Initiated	Guggenheim	Buy
Oct-17-19	Initiated	H.C. Wainwright	Buy	$7
Apr-30-19	Resumed	Noble Capital Markets	Outperform	$13
Jun-15-18	Initiated	JP Morgan	Overweight	$11
Sep-08-17	Initiated	Morgan Stanley	Equal-Weight	$6
Jul-11-17	Upgrade	Oppenheimer	Perform → Outperform
May-09-17	Downgrade	Oppenheimer	Outperform → Perform
Nov-22-16	Resumed	Jefferies	Buy	$18
Nov-22-16	Initiated	Oppenheimer	Outperform
Nov-07-16	Resumed	Guggenheim	Buy
Apr-04-16	Initiated	Goldman	Buy	$10
Dec-08-15	Reiterated	Stifel	Buy	$10 → $14
Dec-08-15	Reiterated	Jefferies	Buy	$15 → $18
Sep-21-15	Reiterated	Jefferies	Buy	$7 → $15
Jun-09-15	Initiated	Guggenheim	Buy
Jul-08-14	Initiated	FBR Capital	Outperform	$34
Apr-17-14	Reiterated	Noble Financial	Buy	$9 → $13
Jan-28-14	Reiterated	Noble Financial	Buy	$7.25 → $9

Show Previous Ratings

May-12-26 04:51PM	TherapeuticsMD: Q1 Earnings Snapshot (Associated Press)
04:05PM	TherapeuticsMD Announces First Quarter 2026 Financial Results (Business Wire)
Mar-30-26 04:05PM	TherapeuticsMD Announces Full Year 2025 Financial Results (Business Wire) -5.24%
Nov-12-25 06:04PM	TherapeuticsMD: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	TherapeuticsMD Announces Third Quarter 2025 Financial Results (Business Wire)
04:47PM	Loading…
Aug-12-25 04:47PM	TherapeuticsMD: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	TherapeuticsMD Announces Second Quarter 2025 Financial Results (Business Wire)
May-13-25 05:02PM	TherapeuticsMD: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	TherapeuticsMD Announces First Quarter 2025 Financial Results (Business Wire)
Mar-27-25 04:05PM	TherapeuticsMD Announces Full Year 2024 Financial Results (Business Wire) -6.48%
Nov-12-24 04:32PM	TherapeuticsMD: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	TherapeuticsMD Announces Third Quarter 2024 Financial Results (Business Wire)
Aug-12-24 05:26PM	TherapeuticsMD: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	TherapeuticsMD Announces Second Quarter 2024 Financial Results (Business Wire)
Jun-28-24 11:52AM	TXMD Stock Earnings: TherapeuticsMD Reported Results for Q4 2023 (InvestorPlace) -7.47%
08:53PM	Loading…
May-10-24 08:53PM	TXMD Stock Earnings: TherapeuticsMD Reported Results for Q1 2024 (InvestorPlace)
04:43PM	TherapeuticsMD: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	TherapeuticsMD Announces First Quarter 2024 Financial Results (Business Wire)
Mar-29-24 04:00PM	TherapeuticsMD Announces Full Year 2023 Financial Results (Business Wire)
Mar-12-24 11:40AM	25 Countries With Highest Abortion Rates (Insider Monkey) +6.95%
Jan-30-24 11:20PM	12 Best Prenatal Vitamins For Pregnant Women (Insider Monkey)
Nov-15-23 05:08AM	TherapeuticsMD: Q3 Earnings Snapshot (Associated Press Finance) +17.41%
Nov-14-23 04:05PM	TherapeuticsMD Announces Third Quarter 2023 Financial Results (Business Wire)
Aug-14-23 07:52AM	TherapeuticsMD: Q2 Earnings Snapshot (Associated Press Finance)
06:50AM	TherapeuticsMD Announces Second Quarter 2023 Financial Results (Business Wire)
May-15-23 05:56PM	TherapeuticsMD: Q1 Earnings Snapshot (AP Finance)
04:05PM	TherapeuticsMD Announces First Quarter 2023 Financial Results (Business Wire)
Apr-14-23 12:00PM	All You Need to Know About TherapeuticsMD (TXMD) Rating Upgrade to Buy (Zacks)
Apr-07-23 04:01PM	TherapeuticsMD Announces Full Year 2022 Financial Results and Provides Update on Business Model Transition (Business Wire)
Jan-03-23 06:50AM	TherapeuticsMD Completes Transaction to License Its Products to Mayne Pharma (Business Wire) +11.81%
10:42AM	Loading…
Dec-08-22 10:42AM	Boca pharma company will cut 212 employees after failed buyout (American City Business Journals)
Dec-04-22 06:00PM	TherapeuticsMD Announces Definitive Agreements to License its Products to Mayne Pharma (Business Wire)
Nov-14-22 07:55PM	TherapeuticsMD (TXMD) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -7.45% -8.20%
04:05PM	TherapeuticsMD Announces Third Quarter 2022 Financial Results (Business Wire)
Oct-31-22 06:50AM	TherapeuticsMD Announces Additional $7 Million Private Placement (Business Wire) +6.21%
Oct-03-22 01:45PM	TherapeuticsMD receives $7M investment after merger plans unravel (American City Business Journals) -7.53%
06:50AM	TherapeuticsMD Announces $7 Million Private Placement (Business Wire)
Sep-12-22 06:50AM	TherapeuticsMD Appoints Dr. Brian Bernick and Mr. Mark Glickman as Interim Co-Chief Executive Officers (Business Wire) +5.55%
Aug-15-22 01:00PM	TherapeuticsMD, Inc. (TXMD) Q2 2022 Earnings Call Transcript (Motley Fool)
08:05AM	TherapeuticsMD (TXMD) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
06:50AM	TherapeuticsMD Announces Second Quarter 2022 Financial Results (Business Wire)
Aug-08-22 06:50AM	TherapeuticsMD to Report Second Quarter 2022 Financial Results on August 15, 2022 (Business Wire)
Aug-01-22 01:00PM	Pharma firm receives $15M investment after canceled merger (American City Business Journals) +36.60%
06:50AM	TherapeuticsMD Secures $15 Million Equity Investment from Rubric Capital (Business Wire)
Jul-15-22 01:34PM	HC Wainwright Rating & Price Target On TherapeuticsMD Under Review On 'Unclear Path' (Benzinga) +12.50%
Jul-13-22 09:48AM	Why TherapeuticsMD Shares Are Sinking Today? (Benzinga) -35.55%
08:25AM	TherapeuticsMD's stock falls 41% after tender offer expires (MarketWatch)
06:50AM	TherapeuticsMD Announces Expiration of Tender Offer (Business Wire)
Jul-06-22 06:09AM	EW Healthcare Partners Announces Extension of TherapeuticsMD Tender Offer (PR Newswire)
Jun-06-22 04:05PM	EW Healthcare Partners Announces Commencement of the Tender Offer for All Outstanding Shares of TherapeuticsMD (PR Newswire)
May-31-22 06:00AM	TherapeuticsMD and EW Healthcare Partners Announce Definitive Agreement for EW Healthcare Partners to acquire TherapeuticsMD (Business Wire) +364.02%
May-20-22 10:52AM	Why TherapeuticsMD Shares Are Trading Higher Today (Benzinga) +36.56%
09:43AM	TherapeuticsMD Receives U.S. Food and Drug Administration (FDA) Approval for Supplemental New Drug Application (sNDA) for ANNOVERA® (Business Wire)
May-16-22 08:00PM	TherapeuticsMD, Inc. (TXMD) Q1 2022 Earnings Call Transcript (Motley Fool) -14.01%
05:45PM	TherapeuticsMD (TXMD) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:05PM	TherapeuticsMD Announces First Quarter 2022 Financial Results (Business Wire)
May-12-22 05:25PM	Harpoon Therapeutics, Inc. (HARP) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -13.87%
May-10-22 04:05PM	TherapeuticsMD to Report First Quarter 2022 Financial Results on May 16, 2022 (Business Wire) -24.78%
Apr-14-22 04:15PM	TherapeuticsMD Completes the Divestiture of vitaCare Prescription Services to GoodRx in a Cash Transaction Valued at $150 Million (Business Wire)
Mar-10-22 01:30PM	TherapeuticsMD, Inc. (TXMD) Q4 2021 Earnings Call Transcript (Motley Fool) -27.50%
08:05AM	TherapeuticsMD (TXMD) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
06:50AM	TherapeuticsMD Announces Fourth Quarter 2021 Financial Results (Business Wire)
Mar-07-22 12:57PM	TherapeuticsMD Shares Soars After VitaCare Divestiture In $150M Deal (Benzinga) +43.05%
07:40AM	TherapeuticsMD Enters Into a Definitive Agreement to Divest vitaCare to GoodRx (Business Wire)
Mar-01-22 04:30PM	TherapeuticsMD to Report Fourth Quarter 2021 Financial Results on March 10, 2022 (Business Wire) -5.69%
Feb-28-22 05:35PM	Nektar Therapeutics (NKTR) Reports Q4 Loss, Lags Revenue Estimates (Zacks) +8.28%
Feb-24-22 09:05AM	Radius Health (RDUS) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
Jan-25-22 08:52AM	TherapeuticsMD, Inc. (NASDAQ:TXMD): Is Breakeven Near? (Simply Wall St.)
Jan-06-22 07:29AM	Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace)
Jan-04-22 06:20AM	FDA Approves TherapeuticsMD's Low Dose Bijuva (Benzinga) +11.18%
Dec-28-21 09:53AM	Implied Volatility Surging for TherapeuticsMD (TXMD) Stock Options (Zacks)
Dec-13-21 06:08AM	TherapeuticsMD's Birth Control Med Receives FDA Response Letter To Revise Manufacturing Testing Limits (Benzinga) -11.51%
Dec-10-21 04:30PM	U.S. Food and Drug Administration (FDA) Responds to Request From TherapeuticsMD to Revise Certain Manufacturing Testing Limits for ANNOVERA® (Business Wire)
Dec-08-21 06:50AM	TherapeuticsMD Settles U.S. Patent Litigation with Amneal for BIJUVA® (Estradiol and Progesterone) Allowing for a May 25, 2032 Generic Entry Date (Business Wire)
Nov-24-21 07:54AM	TherapeuticsMD (NASDAQ:TXMD) investors are sitting on a loss of 90% if they invested five years ago (Simply Wall St.)
Nov-22-21 10:40AM	Therapeuticsmd Insider Trades $580K In Company Stock (Benzinga)
Nov-12-21 03:00AM	TherapeuticsMD, Inc. (TXMD) Q3 2021 Earnings Call Transcript (Motley Fool)
Nov-11-21 06:50AM	TherapeuticsMD Announces Third Quarter 2021 Financial Results (Business Wire) -7.82%
06:45AM	TherapeuticsMD Announces Leadership Changes; Appointment of Industry Veteran, Hugh ODowd, as Chief Executive Officer (Business Wire)
Nov-04-21 03:01PM	TherapeuticsMD (TXMD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Oct-27-21 05:00PM	TherapeuticsMD to Report Third Quarter 2021 Results on November 11, 2021 (Business Wire)
Oct-15-21 05:33PM	TherapeuticsMD Announces Appointment of Mark Glickman as Chief Business Officer (Business Wire)
Oct-05-21 01:28PM	What Type Of Shareholders Own The Most Number of TherapeuticsMD, Inc. (NASDAQ:TXMD) Shares? (Simply Wall St.)
Oct-04-21 09:20AM	Where Do Hedge Funds Stand On TherapeuticsMD Inc (TXMD)? (Insider Monkey)
Sep-02-21 06:50AM	Therapeutics MD Is Urging Women to Take Pause During Menopause Awareness Month (Business Wire) +7.71%
Aug-23-21 06:50AM	TherapeuticsMD Announces Issuance of a J-Code for ANNOVERA® to Be Utilized in the Public Health Sector (Business Wire) +7.12%
Aug-19-21 08:01AM	5 Penny Stocks Insiders Are Buying (Benzinga) +5.53%
Aug-09-21 04:30PM	TherapeuticsMD Announces Appointment of Hugh ODowd as President (Business Wire)
Aug-04-21 08:05AM	TherapeuticsMD (TXMD) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -6.66%
06:50AM	TherapeuticsMD Announces Second Quarter 2021 Financial Results (Business Wire)
Jul-28-21 03:03PM	Will TherapeuticsMD (TXMD) Report Negative Earnings Next Week? What You Should Know (Zacks)
Jul-26-21 06:50AM	TherapeuticsMD to Report Second Quarter 2021 Results on August 4, 2021 (Business Wire)
Jul-06-21 11:49AM	10 Best Pharmaceutical Stocks to Buy According to Billionaire Joseph Edelman (Insider Monkey)
Jun-29-21 08:58AM	Breakeven On The Horizon For TherapeuticsMD, Inc. (NASDAQ:TXMD) (Simply Wall St.)
May-25-21 06:50AM	TherapeuticsMD Announces Submission of Low Dose BIJUVA® 0.5 mg/100 mg Supplemental New Drug Application to FDA (Business Wire)
May-24-21 07:00AM	The Sun Sentinel Names TherapeuticsMD, Inc. a Winner of the South Florida Top Workplaces 2021 Award (Business Wire)
May-07-21 01:31AM	TherapeuticsMD, Inc. (TXMD) Q1 2021 Earnings Call Transcript (Motley Fool)
May-06-21 10:56AM	TherapeuticsMD Shares Plunge On Declining Gross Margin, Total Prescription Volume (Benzinga) -13.28%
08:20AM	TherapeuticsMD (TXMD) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:00AM	TherapeuticsMD Announces First Quarter 2021 Financial Results (Business Wire)

TherapeuticsMD, Inc. operates as a pharmaceutical company. The firm engages in licensing pharmaceutical products and collecting royalties. Its brands include BIJUVA, IMVEXXY, and ANNOVERA. The company was founded by Robert G. Finizio and Brian A. Bernick in 1907 and is headquartered in Boca Raton, FL.

Chief Executive OfficerMr. Marlan D. Walker J.D.

Principal Financial & Accounting OfficerMr. Joseph A. Ziegler

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Thompson Tommy G	Director	Dec 23 '25	Buy	1.67	8,400	14,031	23,179	Dec 29 04:23 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

$100 Off Your First Year Get Elite For Just $199.50

TherapeuticsMD Inc

Upgrade your Finviz experience